Disease and treatment related risk factors associated with poor
neurocognitive domains (Table 4):
Age at diagnosis/initiation of therapy did not affect the neurocognitive
scores. The entire cohort of patients received either prophylactic or
therapeutic cranial radiotherapy(RT). The presence of CNS disease would
entail receiving higher dose of RT to the neuralaxis. Receiving higher
doses of RT to the neuralaxis was also not associated with poorer FSIQs.
Chemotherapy protocol received did not have a directder age at
assessment was associated impact on neurocognitive function. Giving
higher doses of intravenous methotrexate or cytarabine or using triple
IT over IT methotrexate was not associated with increased neurocognitive
deficits(OR: 1.0 , 95% CI 0.3-3.5, p 1.000).